Roche’s Tecentriq/Avastin combo gets liver cancer nod

The FDA has approved Roche’s combination of its Tecentriq and Avastin drugs in previously-untreated hepatocellular carcinoma (HCC) – the most common form of liver cancer.

AZ nabs a positive study for Imfinzi plus tremelimumab in li...

After a long run of trial disappointments, AstraZeneca is celebrating a win for its immuno-oncology combination of Imfinzi plus tremelimumab in advanced liver cancer.

Roche files Tecentriq, Avastin combo as a liver cancer thera...

FDA decision on Opdivo/Yervoy in liver cancer due next March

Sillajen explains Pexa-Vec trial failure – it was the rescue...

BMS has another Opdivo setback after liver cancer trial fail...

Bristol-Myers Squibb’s cancer immunotherapy Opdivo has suffered another setback after it failed to improve on standard care in advanced liver cancer.